Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Canadian warning on Eprex use in cancer patients

Oct. 21, 2004

Enclomiphene increases testosterone in hypogonadal men

Oct. 21, 2004

Vardenafil subject of various presentations at ISSIR

Oct. 20, 2004

Tissue Repair Cell study expanded

Oct. 20, 2004

Clinical evidence of the effects of the SERM HMR-3339 in postmenopausal women

Oct. 20, 2004

Novel glucocorticoid receptor modulators designed at Boehringer Ingelheim

Oct. 20, 2004

Activation of PARP and erectile dysfunction

Oct. 19, 2004

New data on the therapeutic effects of raloxifene in osteoporosis

Oct. 19, 2004

Benefits of a good adherence to bisphosphonates in patients with osteoporosis

Oct. 19, 2004

Luveris approved for concomitant use with Gonal-f

Oct. 19, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...